{"id":10677,"date":"2026-11-04T18:06:43","date_gmt":"2026-11-04T12:36:43","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/emcure-share-price-today-2026-11-04\/"},"modified":"2026-11-04T18:06:45","modified_gmt":"2026-11-04T12:36:45","slug":"emcure-share-price-today-2026-11-04","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/emcure-share-price-today-2026-11-04\/","title":{"rendered":"Emcure Pharmaceuticals Share Price Today: Rises 15.43% in 2 Trading Sessions | 4 November 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: EMCURE<\/strong> \u00b7 4 November 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b92,160.40<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+9.30%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b92,174.20 \/ \u20b92,035.10<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b91,976.60<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>11.90 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>4 November 2026 \u00b7 03:30 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Emcure Pharmaceuticals has risen 15.43% over 2 trading sessions; today&#x27;s move is +9.30%.<\/li>\n<li>Emcure Pharmaceuticals submitted its unaudited financial results for the quarter ended September 30, 2026, reporting operating revenue of \u20b928,205 million, a 24.3% year-on-year increase. Profit after tax rose 29.3% year-on-year to \u20b93,251 million, driven by solid traction across domestic and international markets. EBITDA grew by 30.9% to \u20b95,748 million with margins expanding by 103 basis points to 20.4%.<\/li>\n<li>Trading volume was 8.09 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Emcure Pharmaceuticals share price: 15.43% rise over 2 trading sessions<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Emcure Pharmaceuticals Ltd. (EMCURE) shares moved sharply higher today, surging 9.30% to close at \u20b92,160.40. The stock traded within a daily range of \u20b92,035.10 and \u20b92,174.20, after opening at \u20b92,110.10 compared to its previous close of \u20b91,976.60.<\/p>\n<p class=\"wt-copy\">The broader market and sector indices showed positive momentum, with the benchmark Nifty rising 0.63% and the Nifty Pharma sector gaining 0.42%. Emcure&#x27;s robust double-digit advance significantly outperformed both the broader market and its sector peers, building on strong near-term momentum that includes a 5-day return of 15.96% and a 20-day return of 13.10%.<\/p>\n<p class=\"wt-copy\">The price move follows the company&#x27;s recent Q2FY27 financial results release on November 3, 2026, which reported operating revenue growth of 24.30% year-on-year to \u20b928,205 million and a 29.30% jump in profit after tax to \u20b93,251 million. Management also highlighted strong domestic and international business performance alongside ongoing portfolio expansion across key therapeutic segments, which appears to have strongly supported investor sentiment.<\/p>\n<p class=\"wt-copy\">11.90 lakh shares traded by 4 November 2026 \u00b7 03:30 PM IST. This compares with a 20-day average daily volume of 1.47 lakh shares (8.09 times). The five-day average daily volume was 2.60 lakh shares. Separately, the NSE report for 4 November 2026 showed 4.40 lakh shares delivered, representing 36.98% of that day\u2019s traded volume. The same report recorded 59,392 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Strong Q2 financial results and heavy volume buying<\/strong><\/p>\n<p class=\"wt-copy\">The stock&#x27;s 9.30% rally on volumes exceeding 8 times its 20-day average directly follows the company&#x27;s release of robust Q2FY27 financial results showing a 29.30% rise in net profit and 24.30% revenue growth.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Q2FY27 Financial Results Announcement<\/div>\n<div class=\"wt-card-date\">3 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Emcure Pharmaceuticals submitted its unaudited financial results for the quarter ended September 30, 2026, reporting operating revenue of \u20b928,205 million, a 24.3% year-on-year increase. Profit after tax rose 29.3% year-on-year to \u20b93,251 million, driven by solid traction across domestic and international markets. EBITDA grew by 30.9% to \u20b95,748 million with margins expanding by 103 basis points to 20.4%.<\/p>\n<p class=\"wt-copy\">Strong quarterly earnings and margin expansion directly validate the company&#x27;s growth trajectory and operational efficiency.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Proposed Scheme of Amalgamation for Subsidiaries<\/div>\n<div class=\"wt-card-date\">12 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The board of directors approved a proposed scheme of amalgamation for wholly owned subsidiaries Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited with the holding company, Emcure Pharmaceuticals Limited. The restructuring is subject to requisite statutory and regulatory approvals. It forms part of the &#x27;One Emcure&#x27; vision to simplify the group holding structure.<\/p>\n<p class=\"wt-copy\">Simplifying the group structure aims to achieve operational synergies and streamline backend and corporate functions.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/EMCURE_12102026103306_OutcomeofBM12102026_Final.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Income Tax Penalty Disclosure<\/div>\n<div class=\"wt-card-date\">3 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company disclosed the receipt of various orders from the Income-tax Department imposing an aggregate penalty of \u20b957,73,96,732 for financial years 2014-15 to 2020-21. Emcure stated that it is evaluating appropriate legal remedies, including filing appeals before the appropriate Appellate Authority.<\/p>\n<p class=\"wt-copy\">Discloses potential tax liabilities and ongoing litigation items that the company is actively contesting.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/EMCURE_02102026213119_EPLReg30IntimationOrder.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Outcome of Board Meeting<\/div>\n<div class=\"wt-card-date\">3 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/EMCURE_03112026134234_EPLOutcomeofBMQ2FY27.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Earnings \/ operating update<\/div>\n<div class=\"wt-card-date\">3 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/EMCURE_03112026134234_EPLOutcomeofBMQ2FY27.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">77.82%<\/div>\n<div class=\"wt-note\">77.83% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">4.94%<\/div>\n<div class=\"wt-note\">4.88% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">13.43%<\/div>\n<div class=\"wt-note\">13.34% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1741485_19102026034802_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 7.05% on 30 September 2026. This compares with 6.87% on 30 June 2026, a change of +0.18 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 23 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Kotak Midcap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">43.82 lakh shares \u00b7 2.31%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Aditya Birla Sun Life Mutual Fund &#8211; Aditya Birla Sun Life Elss Tax Saver Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">27.42 lakh shares \u00b7 1.45%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Nippon Life India Trustee Ltd-A\/C Nippon India Multi Cap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">22.58 lakh shares \u00b7 1.19%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1741485_19102026034802_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div class=\"wt-grid wt-grid-brokerage\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Angel One<\/div>\n<div class=\"wt-card-date\">25 June 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Buy<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Analyst Osho Krishan highlighted Emcure shares as a technical buy recommendation alongside other key market stocks.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">Bc Investments Iv Limited<\/div>\n<div class=\"wt-card-date\">25 June 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 9.70 lakh shares \u00b7 \u20b91,817.00<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">Bc Investments Iv Limited<\/div>\n<div class=\"wt-card-date\">25 June 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 9.70 lakh shares \u00b7 \u20b91,817.00<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">Hdfc Standard Life Insurance Company Ltd<\/div>\n<div class=\"wt-card-date\">25 June 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 5.57 lakh shares \u00b7 \u20b91,817.00<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">Aditya Birla Sun Life Mutual Fund<\/div>\n<div class=\"wt-card-date\">25 June 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 2.61 lakh shares \u00b7 \u20b91,817.00<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution and regulatory approvals regarding the proposed amalgamation of Zuventus Healthcare and Emcutix Biopharmaceuticals.<\/li>\n<li>Sustained delivery and volume participation relative to the 20-day average volume of 8.09x seen today.<\/li>\n<li>Progress on international market pipelines including Canada and RoW non-ARV product approvals.<\/li>\n<li>Updates regarding legal remedies pursued against the Income-tax Department penalty orders.<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/emcure-share-price-today-2026-11-03\/\">Emcure Pharmaceuticals Share Price Jumps 10.00% Intraday, Closes 4.94% Higher | 3 November 2026 \u2014 3 November 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/emcure\/\">More Emcure Pharmaceuticals news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Emcure Pharmaceuticals company news?<\/h3>\n<p class=\"wt-copy\">Emcure Pharmaceuticals submitted its unaudited financial results for the quarter ended September 30, 2026, reporting operating revenue of \u20b928,205 million, a 24.3% year-on-year increase. Profit after tax rose 29.3% year-on-year to \u20b93,251 million, driven by solid traction across domestic and international markets. EBITDA grew by 30.9% to \u20b95,748 million with margins expanding by 103 basis points to 20.4%.<\/p>\n<h3>How strong was Emcure Pharmaceuticals\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">11.90 lakh shares traded, 8.09 times the 20-day average daily volume. The price and volume data are dated 4 November 2026 \u00b7 03:30 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/emcure-share-price-today-2026-11-04\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/emcure-share-price-today-2026-11-04\/\"}, \"headline\": \"Emcure Pharmaceuticals Share Price Today: Rises 15.43% in 2 Trading Sessions | 4 November 2026\", \"description\": \"Emcure Pharmaceuticals has risen 15.43% over 2 trading sessions. Today it is 9.30% higher at \u20b92,160.40. See price context, volume and key company developments.\", \"datePublished\": \"2026-11-04T18:06:32.228599+05:30\", \"dateModified\": \"2026-11-04T18:06:32.228599+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Emcure Pharmaceuticals\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"EMCURE\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/11\/emcure-company-news-2026-11-04.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Outcome of Board Meeting\",\"summary\":\"Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"source\":\"NSE\",\"published\":\"03-Nov-2026 13:44:22\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/EMCURE_03112026134234_EPLOutcomeofBMQ2FY27.pdf\"}],\"recent_news\":[{\"summary\":\"Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"03-Nov-2026 13:44:22\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/EMCURE_03112026134234_EPLOutcomeofBMQ2FY27.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Emcure Pharmaceuticals Q2 Results: Profit Jumps 34%, Revenue Up 24%.\",\"category\":\"Business media\",\"published\":\"2026-11-03T09:38:25+00:00\",\"source\":\"Business media\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Emcure Pharma Q2FY27 results: Net profit rises 29.31% to \u20b9325 crore.\",\"category\":\"Business media\",\"published\":\"2026-11-03T11:36:55+00:00\",\"source\":\"Business media\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Emcure Pharmaceuticals Limited has informed the Exchange that the Board of Directors at the meeting held on October 12, 2026 have approved the proposed Scheme of Amalgamation of Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, wholly owned subsidiaries with Emcure Pharmaceuticals Limited - Holding Company, subject to requisite statutory and regulatory approvals.\",\"category\":\"Amalgamation\/Merger\",\"date\":\"12-Oct-2026 10:33:18\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/EMCURE_12102026103306_OutcomeofBM12102026_Final.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":5}],\"promoter_pledge\":{\"summary\":\"Smita Paresh Shah, part of the promoter group has pledged 60,000 Equity Shares of the Company during the Financial Year 2024-25 and the said equity shares continue to remain pledged as on March 31, 2026.\",\"events\":[{\"summary\":\"Smita Paresh Shah, part of the promoter group has pledged 60,000 Equity Shares of the Company during the Financial Year 2024-25 and the said equity shares continue to remain pledged as on March 31, 2026.\",\"category\":\"Disclosure under SEBI Takeover Regulations\",\"date\":\"24-Jun-2026 17:18:15\",\"source\":\"NSE corporate filing\",\"attachment\":\"https:\/\/nsearchives.nseindia.com\/corporate\/team_sandeshc_23062026124540_45.pdf\",\"detail_level\":\"pdf_facts\"}],\"source\":\"NSE corporate filing\"},\"shareholding_snapshot\":{\"promoter_pct\":77.82,\"public_pct\":22.18,\"fii_pct\":4.94,\"dii_pct\":8.49,\"mf_pct\":7.05,\"institutional_pct\":13.43,\"noninst_pct\":8.75,\"mf_scheme_count\":23,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Kotak Midcap Fund\",\"shares\":4381625,\"pct\":2.31},{\"name\":\"Aditya Birla Sun Life Mutual Fund - Aditya Birla Sun Life Elss Tax Saver Fund\",\"shares\":2742491,\"pct\":1.45},{\"name\":\"Nippon Life India Trustee Ltd-A\/C Nippon India Multi Cap Fund\",\"shares\":2257585,\"pct\":1.19}],\"period\":\"30-SEP-2026\",\"submission_date\":\"19-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1741485_19102026034802_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":77.83,\"previous_fii_pct\":4.88,\"previous_dii_pct\":8.46,\"previous_mf_pct\":6.87,\"previous_institutional_pct\":13.34,\"previous_mf_scheme_count\":23,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"brokerage_views\":[{\"brokerage\":\"Kotak\",\"rating\":\"Buy\",\"target\":null,\"view_summary\":\"Stocks to buy or sell: Osho Krishan of Angel One suggests buying Kotak Mahindra Bank, Emcure shares to buy Livemint\",\"headline\":\"Stocks to buy or sell: Osho Krishan of Angel One suggests buying Kotak Mahindra Bank, Emcure shares to buy\",\"published\":\"2026-03-26T07:00:00+00:00\",\"source\":\"Livemint\"}],\"bulk_block_deals\":[{\"deal_type\":\"Block\",\"date\":\"25 Jun, 2026\",\"party\":\"Bc Investments Iv Limited\",\"side\":\"Sell\",\"quantity\":\"969730\",\"price\":\"1,817\",\"source\":\"Public market-data page\",\"value\":\"\u20b9176.20 Cr\"},{\"deal_type\":\"Block\",\"date\":\"25 Jun, 2026\",\"party\":\"Bc Investments Iv Limited\",\"side\":\"Sell\",\"quantity\":\"969729\",\"price\":\"1,817\",\"source\":\"Public market-data page\",\"value\":\"\u20b9176.20 Cr\"},{\"deal_type\":\"Block\",\"date\":\"25 Jun, 2026\",\"party\":\"Hdfc Standard Life Insurance Company Ltd\",\"side\":\"Buy\",\"quantity\":\"556954\",\"price\":\"1,817\",\"source\":\"Public market-data page\",\"value\":\"\u20b9101.20 Cr\"},{\"deal_type\":\"Block\",\"date\":\"25 Jun, 2026\",\"party\":\"Aditya Birla Sun Life Mutual Fund\",\"side\":\"Buy\",\"quantity\":\"261420\",\"price\":\"1,817\",\"source\":\"Public market-data page\",\"value\":\"\u20b947.50 Cr\"},{\"deal_type\":\"Block\",\"date\":\"25 Jun, 2026\",\"party\":\"Hdfc Standard Life Insurnace\",\"side\":\"Buy\",\"quantity\":\"157949\",\"price\":\"1,817\",\"source\":\"Public market-data page\",\"value\":\"\u20b928.70 Cr\"},{\"deal_type\":\"Block\",\"date\":\"25 Jun, 2026\",\"party\":\"Alpha Alternatives Equity Absolute Return Fund\",\"side\":\"Buy\",\"quantity\":\"137593\",\"price\":\"1,817\",\"source\":\"Public market-data page\",\"value\":\"\u20b925.00 Cr\"},{\"deal_type\":\"Block\",\"date\":\"25 Jun, 2026\",\"party\":\"Bnp Paribas Financial Markets\",\"side\":\"Buy\",\"quantity\":\"137592\",\"price\":\"1,817\",\"source\":\"Public market-data page\",\"value\":\"\u20b925.00 Cr\"},{\"deal_type\":\"Block\",\"date\":\"25 Jun, 2026\",\"party\":\"Axis Mutual Fund\",\"side\":\"Buy\",\"quantity\":\"137591\",\"price\":\"1,817\",\"source\":\"Public market-data page\",\"value\":\"\u20b925.00 Cr\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Emcure Pharmaceuticals has risen 15.43% over 2 trading sessions. Today it is 9.30% higher at \u20b92,160.40. See price context, volume and key company developments.<\/p>\n","protected":false},"author":1,"featured_media":10676,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Emcure Pharmaceuticals Share Price Today: Rises 15.43% in 2 Trading Sessions | 4 November 2026","_witty_meta_description":"Emcure Pharmaceuticals has risen 15.43% over 2 trading sessions. Today it is 9.30% higher at \u20b92,160.40. See price context, volume and key company developments.","_witty_primary_phrase":"Emcure Pharmaceuticals share price today","_witty_reason_label":"Strong Q2 financial results and heavy volume buying","_witty_reason_confidence":"high","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[404],"class_list":["post-10677","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-emcure"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/10677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=10677"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/10677\/revisions"}],"predecessor-version":[{"id":10678,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/10677\/revisions\/10678"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/10676"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=10677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=10677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=10677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}